BioAtla‘s patent discloses a method, Comprehensive Integrated Antibody Optimization (CIAO!™), for generating and optimizing therapeutic proteins, including antibodies, in a single eukaryotic host system. The method involves mutating proteins, screening for desired properties, selecting optimal mutants, and manufacturing them in the same host. GlobalData’s report on BioAtla gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on BioAtla, Personalized cancer vaccines was a key innovation area identified from patents. BioAtla's grant share as of May 2024 was 31%. Grant share is based on the ratio of number of grants to total number of patents.
Method of evolving therapeutic proteins in eukaryotic host system
A recently granted patent (Publication Number: US11976381B2) outlines a method for the evolution of a template human protein in a manufacturing host. The process involves mutating the template human protein to generate a set of mutant human proteins in the manufacturing host, with the incorporation of an unnatural amino acid. These mutant proteins are then screened for specific properties, characteristics, or activities, with an up-mutant human protein selected based on predetermined criteria. The selected up-mutant human protein is then manufactured by expressing it in the same manufacturing host used during the mutation step.
Furthermore, the method includes steps for optimizing the selected up-mutant human protein by enhancing its expression and modifying it compared to the template human protein. The screening process can be conducted under conditions that mimic manufacturing conditions, in cell-free environments, or even in non-human living organisms. Additionally, the method allows for the identification and selection of mutant human proteins that do not trigger an undesirable immune response. The patent covers a wide range of human proteins, including antibodies, enzymes, cytokines, receptors, DNA binding proteins, chelating agents, and hormones, with the evolution process taking place in a eukaryotic cell production host with cell surface display capabilities. The up-mutant human protein may contain silent mutations and/or missense mutations to enhance its properties and characteristics.
To know more about GlobalData’s detailed insights on BioAtla, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
